Opaleye Management’s Journey Medical DERM Stock Holding History

Opaleye Management’s Portfolio DERM Stock Details DERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48M	Sell	350,000 -610,000	-64%	-$3.48M	0.22%	45
2026 Q1	$4.5M	Sell	960,000 -15,000	-2%	-$116K	0.59%	33
2025 Q4	$7.52M	Buy	975,000 +3,936	+0.4%	+$30.9K	0.99%	25
2025 Q3	$6.91M	Buy	971,064 +876,064	+922%	+$6.35M	0.98%	24
2025 Q2	$682K	Buy	95,000 +25,677	+37%	+$177K	0.14%	37
2025 Q1	$409K	Buy	+69,323	New	+$341K	0.09%	43
2022 Q4	–	Sell	-259,293	Closed	-$638K	–	42
2022 Q3	$638K	Buy	259,293 +13,560	+6%	+$46.2K	0.26%	33
2022 Q2	$919K	Buy	245,733 +178,733	+267%	+$707K	0.41%	37
2022 Q1	$324K	Buy	+67,000	New	+$334K	0.1%	44

Other funds holding DERM

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAIM

Punch & Associates Investment Management Edina, Minnesota $2.02B AUM 40.6% 1-Year Est. Return

PFCS

Pale Fire Capital SE Prague, Czech Republic $1.41B AUM 25.22% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management's DERM Position: Q2 2026 in Review

Opaleye Management reduced its Journey Medical (DERM) stake by 64% in Q2 2026, selling an estimated $3.48M and leaving 350,000 shares worth $2.48M. The position accounts for 0.22% of the portfolio, ranked #45.

Opaleye Management first reported a position in DERM in Q1 2022 and has held it in 9 quarters since. The position peaked at $7.52M in Q4 2025. 71 funds tracked by Wall St. Rank hold DERM as of Q2 2026.

Opaleye Management held 350,000 shares of Journey Medical worth $2.48M as of Q2 2026.
Opaleye Management sold 610,000 Journey Medical shares in Q2 2026, an estimated $3.48M.
Journey Medical made up 0.22% of Opaleye Management's portfolio in Q2 2026, its #45 holding.
Opaleye Management first reported a position in Journey Medical in Q1 2022 and has held it in 9 quarters since.
Opaleye Management's Journey Medical position peaked at $7.52M in Q4 2025.
71 funds tracked by Wall St. Rank held Journey Medical as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.